Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
5.17
-0.11 (-2.08%)
Oct 27, 2025, 4:00 PM EDT - Market closed
Sight Sciences Revenue
Sight Sciences had revenue of $19.56M in the quarter ending June 30, 2025, a decrease of -8.45%. This brings the company's revenue in the last twelve months to $76.30M, down -3.89% year-over-year. In the year 2024, Sight Sciences had annual revenue of $79.87M, down -1.47%.
Revenue (ttm)
$76.30M
Revenue Growth
-3.89%
P/S Ratio
3.46
Revenue / Employee
$353,255
Employees
216
Market Cap
270.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 79.87M | -1.19M | -1.47% |
| Dec 31, 2023 | 81.06M | 9.73M | 13.63% |
| Dec 31, 2022 | 71.33M | 22.38M | 45.70% |
| Dec 31, 2021 | 48.96M | 21.32M | 77.12% |
| Dec 31, 2020 | 27.64M | 4.29M | 18.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SGHT News
- 4 days ago - Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 10 days ago - Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure - GlobeNewsWire
- 5 weeks ago - Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use - GlobeNewsWire
- 6 weeks ago - Sight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 6 weeks ago - Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments - GlobeNewsWire
- 7 weeks ago - Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO - GlobeNewsWire
- 2 months ago - Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript - Seeking Alpha